NO175642C - Hovedsakelig rent humant tumor gp580 antigen, fremgangsmåte for fremstilling derav, antistoff mot dette, kontinuerlig hybrid cellelinje som produserer antistoffet og anvendelse av antistoffet ved in vitro diagnose - Google Patents

Hovedsakelig rent humant tumor gp580 antigen, fremgangsmåte for fremstilling derav, antistoff mot dette, kontinuerlig hybrid cellelinje som produserer antistoffet og anvendelse av antistoffet ved in vitro diagnose

Info

Publication number
NO175642C
NO175642C NO871352A NO871352A NO175642C NO 175642 C NO175642 C NO 175642C NO 871352 A NO871352 A NO 871352A NO 871352 A NO871352 A NO 871352A NO 175642 C NO175642 C NO 175642C
Authority
NO
Norway
Prior art keywords
antibody
human tumor
antigen
production
cell line
Prior art date
Application number
NO871352A
Other languages
English (en)
Norwegian (no)
Other versions
NO871352D0 (no
NO175642B (sv
NO871352L (no
Inventor
Garth L Nicolson
Susan M North
Peter A Steck
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO871352D0 publication Critical patent/NO871352D0/no
Publication of NO871352L publication Critical patent/NO871352L/no
Publication of NO175642B publication Critical patent/NO175642B/no
Publication of NO175642C publication Critical patent/NO175642C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communication Control (AREA)
  • Stereophonic System (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Air Conditioning Control Device (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
NO871352A 1986-04-01 1987-03-31 Hovedsakelig rent humant tumor gp580 antigen, fremgangsmåte for fremstilling derav, antistoff mot dette, kontinuerlig hybrid cellelinje som produserer antistoffet og anvendelse av antistoffet ved in vitro diagnose NO175642C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/846,938 US5030559A (en) 1986-04-01 1986-04-01 Methods and compositions for the identification of metastatic human tumors

Publications (4)

Publication Number Publication Date
NO871352D0 NO871352D0 (no) 1987-03-31
NO871352L NO871352L (no) 1987-10-02
NO175642B NO175642B (sv) 1994-08-01
NO175642C true NO175642C (no) 1994-11-09

Family

ID=25299361

Family Applications (1)

Application Number Title Priority Date Filing Date
NO871352A NO175642C (no) 1986-04-01 1987-03-31 Hovedsakelig rent humant tumor gp580 antigen, fremgangsmåte for fremstilling derav, antistoff mot dette, kontinuerlig hybrid cellelinje som produserer antistoffet og anvendelse av antistoffet ved in vitro diagnose

Country Status (11)

Country Link
US (1) US5030559A (sv)
EP (1) EP0240341B1 (sv)
JP (1) JPH0742320B2 (sv)
AT (1) ATE105569T1 (sv)
AU (1) AU599364B2 (sv)
CA (1) CA1307478C (sv)
DE (1) DE3789781T2 (sv)
DK (1) DK162387A (sv)
ES (1) ES2051737T3 (sv)
FI (1) FI89806C (sv)
NO (1) NO175642C (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE403802B (sv) * 1972-10-10 1978-09-04 Buchegger Masch Reinigung Anordning for rengoring och avfettning av maskindelar och liknande
US5648223A (en) * 1994-08-31 1997-07-15 Activated Cell Therapy, Inc. Methods for enriching breast tumor cells
US5646004A (en) * 1994-08-31 1997-07-08 Activated Cell Therapy, Inc. Methods for enriching fetal cells from maternal body fluids
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US5663051A (en) * 1994-08-31 1997-09-02 Activated Cell Therapy, Inc. Separation apparatus and method
DE19530273C1 (de) * 1995-08-17 1996-12-12 Univ Eberhard Karls Antikörper 105A5
DE19530272C1 (de) * 1995-08-17 1996-11-21 Univ Eberhard Karls Antikörper 103 B2
BR0115715A (pt) * 2000-11-28 2004-02-03 Wyeth Corp Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
HUP0303899A3 (en) * 2000-11-28 2007-05-02 Wyeth Corp Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP2295606A1 (en) * 2000-11-28 2011-03-16 Wyeth LLC Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7169722B2 (en) * 2002-01-28 2007-01-30 Guardian Industries Corp. Clear glass composition with high visible transmittance
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
TW200821026A (en) * 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2721140B1 (en) * 2011-06-19 2016-11-23 Abogen, Inc. Devices, solutions and methods for sample collection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697638A (en) * 1970-06-01 1972-10-10 Hoffmann La Roche Antigens
US4140753A (en) * 1976-04-30 1979-02-20 Scripps Clinic & Research Foundation Diagnostic method and reagent
US4145336A (en) * 1976-04-30 1979-03-20 Scripps Clinic And Research Foundation Carcinoembryonic antigen isomer
IN150740B (sv) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3586216T2 (de) * 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.

Also Published As

Publication number Publication date
NO871352D0 (no) 1987-03-31
EP0240341A2 (en) 1987-10-07
FI871411A0 (fi) 1987-03-31
EP0240341A3 (en) 1989-07-19
NO175642B (sv) 1994-08-01
JPS62253395A (ja) 1987-11-05
ATE105569T1 (de) 1994-05-15
DE3789781D1 (de) 1994-06-16
FI871411A (fi) 1987-10-02
AU599364B2 (en) 1990-07-19
DK162387D0 (da) 1987-03-31
JPH0742320B2 (ja) 1995-05-10
AU7075387A (en) 1987-10-08
EP0240341B1 (en) 1994-05-11
DE3789781T2 (de) 1994-11-10
NO871352L (no) 1987-10-02
US5030559A (en) 1991-07-09
DK162387A (da) 1987-10-02
ES2051737T3 (es) 1994-07-01
FI89806C (sv) 1993-11-25
FI89806B (fi) 1993-08-13
CA1307478C (en) 1992-09-15

Similar Documents

Publication Publication Date Title
NO175642C (no) Hovedsakelig rent humant tumor gp580 antigen, fremgangsmåte for fremstilling derav, antistoff mot dette, kontinuerlig hybrid cellelinje som produserer antistoffet og anvendelse av antistoffet ved in vitro diagnose
EP1630235A3 (en) Compounds for immunodiagnosis of prostate cancer and method for their use
EP0288082A3 (en) A tumor specific assay for ca125 ovarian cancer antigen
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
ATE13198T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches t-zellenantigen, antikoerper und verfahren.
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ES8609731A1 (es) Un metodo para diagnosticar una condicion neoplastica en un hospedante mamifero
AU3878697A (en) Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
CA2037105A1 (en) Diagnostic assay for alzheimer's disease
ATA208987A (de) Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel
EP0118891A3 (en) Monoclonal antibodies to human bladder and ureter cancers and method
PH17490A (en) Hybrid cell line for producing monoclonal antibody to a human early thymocyte antigen,antibody and methods
CA2045552A1 (en) Cancer related haptoglobin
ES8307377A1 (es) Un procedimiento para detectar la localizacion del producto de reaccion antigeno-anticuerpoen la celulas malignas.
EP0273453A3 (en) Hybridoma cell lines and monoclonal antibodies to angiotensin ii
ES8707863A1 (es) Un procedimiento para producir un anticuerpo monoclonal para carcinoma de pulmon humano de celulas no pequenas.
EP0143367A3 (en) Method for production of monoclonal antibodies for cancer diagnosis and therapy
Salinas et al. Tumor burden and its relationship to antigen, size and composition of immune complexes
EP0356397A3 (en) Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
EP0040020A3 (en) Human reverse transcriptase enzyme, method for its purification, and its use in the detection of breast cancer
AU538833B2 (en) Method of diagnosing arterosclerosis
JPS643199A (en) Monoclonal antibody
EP0272113A3 (en) Anti-human cancer monoclonal antibodies
Oltrogge et al. How to overcome the disturbing effects of human anti-mouse antibodies (HAMA) on in vitro assays
Salinas et al. Antigenic heterogeneity as reflected by interaction with antibody (Ab) and circulating immune complexes (CIC) in sarcoma patients